313345-14-1

Upstream product

• 264608-14-2 2-chloro-N-(2,2-diphenylethyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 
• 64-17-5 ethanol 
• 201230-82-2 carbon monoxide 

Downstream Products

• 380221-63-6 6-[(2,2-Diphenylethyl)amino]-9-{(2R,3R,4S,5S)-5-[(ethylamino)carbonyl]-3,4-dihydroxytetrahydro-2-furanyl}-N-(2-[({[1-(2-pyridinyl)-4-piperidinyl]amino}carbonyl)amino]ethyl)-9H-purine-2-carboxamide 
• 1360054-66-5 N-(2,2-diphenylethyl)-2-(ethoxycarbonyl)-2',3'-O-isopropylidene-adenosine hydrogen sulfate 
• 380222-90-2 C₃₀H₃₁N₅O₇ 
• 1360054-67-6 C₄H₁₁N*C₃₀H₃₂N₆O₆ 
• 380222-94-6 9-{(3AR,4R,6S,6AS)-6-[(ethylamino)carbonyl]-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl}-6-[(2,2-diphenylethyl)amino]-N-{2-[({[1-(2-pyridinyl)-4-piperidinyl]amino}carbonyl)amino]ethyl}-9H-purine-2-carboxamide 
• 313345-09-4 6-[(2,2-diphenylethyl)amino]-9-(tetrahydro-2H-pyran-2-yl)-9H-purine-2-carboxylic acid 

Relevant academic research and scientific papers

Route selection and process development of a multikilogram route to the inhaled A2a agonist UK-432,097

This article describes the selection, process development, and scale-up of a synthetic route to a complex nucleoside analogue, the A2a agonist UK-432,097 (1), that culminated in the manufacture of over 25 kg of the API. The key steps in the process were (1) a stereoselective glycosidation reaction; (2) a scalable bleach-TEMPO oxidation; and (3) an unusual elevated temperature crystallization process for the final API. The problems that were encountered with the scale-up of the route together with how they were overcome are also presented.

Purine derivatives

The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds as adenosine A2a receptor agonists.